SCID screening improves medical outcomes with early detection,
intervention
WALTHAM, Mass.--(BUSINESS WIRE)--
PerkinElmer,
Inc., a global leader in improving the health and safety of people
and the environment, today introduced the first commercially available
screening test for Severe
Combined Immunodeficiency (SCID). The EnLite™ Neonatal TREC System
expands the newborn screening portfolio of commercially available tests
and will be introduced under CE marking, for sale in select countries in
Europe and the Middle East.
SCID impacts an estimated 1 in 50,000 to 1 in 100,000 newborns globally
every year. The disease is a genetic disorder that can reduce lifespan
but it can be treated when detected early in newborns. Treatments
include bone marrow or cord
blood transplant (BMT/CBT) from a family member or donor.
PerkinElmer's new SCID screening test provides a benefit over current
laboratory tests by reducing steps in the workflow, thus increasing
screening efficiency.
Implementing screening for early detection of SCID as part of a newborn
screening program provides a cost benefit compared to the greater costs
of managing the disease when detected later. This is due to fewer
complications that require prolonged and intensive care as a result of
the earlier detection and diagnosis of SCID.
"PerkinElmer has been a global leader in newborn screening for more than
25 years. Our new SCID screening test is the direct result of our
extensive expertise, knowledge and commitment to ensuring that newborn
screening laboratories have access to the most advanced testing products
for improving the health of babies," said Jim Corbett, president,
Diagnostics and Life Sciences and Technology, PerkinElmer. "We are
pleased to offer this new screening test to many countries in Europe and
the Middle East so that they can incorporate it as part of their
pre-existing newborn screening programs for early detection of this
genetic disorder and timely clinical intervention for improved medical
outcomes."
"We have seen that early clinical intervention is key to allowing
effective management for patients with Severe Combined
Immunodeficiency," said Bobby Gaspar, M.D, Ph.D., Professor of
Pediatrics and Immunology at London's Great Ormond Street Hospital for
Children and the UCL Institute of Child Health. "With the availability
of PerkinElmer's new test for screening SCID, clinicians will be able to
diagnose patients more quickly and precisely, improving quality of life
and transplant outcome for newborns affected by this highly debilitating
and potentially fatal condition."
Screening through the EnLite™ Neonatal TREC System is intended to
provide accurate results and minimize the number of steps taken towards
a SCID diagnosis. The simplified procedure is designed to be cost
effective and fit within the existing newborn screening processes that
are utilized by laboratories. The test has been designed to minimize
manual work and the risk of contamination by reducing the number of
transfer steps. The test includes software-aided traceability for the
workflow that is intended to improve safety and efficacy in the
screening use.
To learn more about PerkinElmer's newborn screening platforms, visit: www.perkinelmer.com/newbornscreening.
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and
safety of people and the environment. The company reported revenue of
approximately $2.1 billion in 2012, has about 7,500 employees serving
customers in more than 150 countries, and is a component of the S&P 500
Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
Join the conversation and follow us on twitter at www.twitter.com/perkinelmernews
About Great Ormond Street Hospital for Children NHS Foundation Trust
The UCL Institute of Child Health, in partnership with Great Ormond
Street Hospital (GOSH), is the largest centre in Europe devoted to
clinical and basic research and postgraduate teaching in children's
health. Academics at the UCL Institute of Child Health work together
with clinicians at GOSH to form an integrated and multi-disciplinary
approach to the understanding, diagnosis, treatment and prevention of
childhood disease. Many individuals hold joint appointments at both
institutions. This allows the hospital and the institute to work
together to translate research undertaken in laboratories into clinical
trials and treatments in the hospital, bringing real benefits to the
children at GOSH and to the wider paediatric community. See www.ucl.ac.uk/ich/homepage
for more information.
Edelman (On behalf of PerkinElmer, Inc.)
Jen Reid, 404-460-8587
jen.reid@edelman.com
Source: PerkinElmer
News Provided by Acquire Media